These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12681230)

  • 1. Translating the human genome: renaissance of cardiovascular receptor pharmacology.
    Davenport AP; Macphee CH
    Curr Opin Pharmacol; 2003 Apr; 3(2):111-3. PubMed ID: 12681230
    [No Abstract]   [Full Text] [Related]  

  • 2. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
    Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
    Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system.
    Katugampola S; Davenport A
    Trends Pharmacol Sci; 2003 Jan; 24(1):30-5. PubMed ID: 12498728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Beneficial Cardiovascular Effects of Natural Activators of Autophagy.
    Frati G; Vecchione C; Sciarretta S
    Circ Res; 2018 Sep; 123(8):947-949. PubMed ID: 30355035
    [No Abstract]   [Full Text] [Related]  

  • 5. Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system.
    Katugampola SD; Maguire JJ; Kuc RE; Wiley KE; Davenport AP
    Can J Physiol Pharmacol; 2002 May; 80(5):369-74. PubMed ID: 12056541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular receptors as drug targets. Eur omega Conferences' Cardiovascular receptors as drug targets. Institut Pasteur, Paris, France, 3-4 October 1996.
    Maack T
    Mol Med Today; 1997 Mar; 3(3):101-2. PubMed ID: 9095483
    [No Abstract]   [Full Text] [Related]  

  • 7. Protein sorting gone wrong--VPS10P domain receptors in cardiovascular and metabolic diseases.
    Schmidt V; Willnow TE
    Atherosclerosis; 2016 Feb; 245():194-9. PubMed ID: 26724530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Future of Cardiovascular Therapeutics.
    MacRae CA; Roden DM; Loscalzo J
    Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
    [No Abstract]   [Full Text] [Related]  

  • 9. Two sides of the one coin-the cardiac and vascular system.
    Loudon JA
    Cardiovasc Drugs Ther; 2014 Apr; 28(2):199-201. PubMed ID: 24281898
    [No Abstract]   [Full Text] [Related]  

  • 10. Leptin and the cardiovascular system - a target for therapeutic interventions.
    Beltowski J
    Curr Pharm Des; 2014; 20(4):601-2. PubMed ID: 23688018
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic potential of neuregulin-1 in cardiovascular disease.
    Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of quercetin in vascular physiology.
    Chirumbolo S
    Can J Physiol Pharmacol; 2012 Dec; 90(12):1652-7. PubMed ID: 23210445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of gap junctions in the cardiovascular system.
    Dhein S
    Cardiovasc Res; 2004 May; 62(2):287-98. PubMed ID: 15094349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of adhesion molecules in cardiovascular pharmacology: meeting review.
    Virkhaus R; Lucchesi BR; Simpson PJ; Shebuski RJ
    J Pharmacol Exp Ther; 1995 May; 273(2):569-75. PubMed ID: 7752057
    [No Abstract]   [Full Text] [Related]  

  • 15. P2X and P2Y nucleotide receptors as targets in cardiovascular disease.
    Kennedy C; Chootip K; Mitchell C; Syed NI; Tengah A
    Future Med Chem; 2013 Mar; 5(4):431-49. PubMed ID: 23495690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system.
    Nagatomo T; Rashid M; Abul Muntasir H; Komiyama T
    Pharmacol Ther; 2004 Oct; 104(1):59-81. PubMed ID: 15500909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular pharmacology (IV). The current validity of "old" drugs: beta-blockers].
    Permanyer Miralda G; Sanz Girgas E
    Rev Esp Cardiol; 1994 Sep; 47(9):616-25. PubMed ID: 7973029
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular disease strategies--directions after the human genome.
    Barone FC
    Curr Opin Investig Drugs; 2006 Sep; 7(9):789-91. PubMed ID: 17002255
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin II- and Alzheimer-Type Cardiovascular Aging.
    Cooper HA; Scalia R; Rizzo V; Eguchi S
    Circ Res; 2018 Aug; 123(6):651-653. PubMed ID: 30355238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular remodeling and the peripheral serotonergic system.
    Ayme-Dietrich E; Aubertin-Kirch G; Maroteaux L; Monassier L
    Arch Cardiovasc Dis; 2017 Jan; 110(1):51-59. PubMed ID: 28017279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.